In our enivonment, the use of these pulsatile-flow VAD as BTT is a feasible strategy that obtains similar outcomes to those of intracorporeal continuous-flow devices. The most frequent complications were infectious, and the most severe were neurological. ConclusionsĮighty percent of patients with the EXCOR VAD as BTT achieved the goal after an average of almost 4 months of support. The main complications included infectious (52% of patients), neurological events (32%, half of them fatal), bleeding (28%), and VAD malfunction requiring component replacement (28%). Twenty patients (80%) were successfully bridged to heart transplant after a median of 112 days (range, 8-239). Ventricular assist devices were indicated directly as a BTT in 12 patients and as a bridge to decision in 13 due to the presence of potentially reversible contraindications or chance of heart function recovery. Resultsĭuring the study period, 25 VADs were implanted, 6 of them biventricular.

Retrospective analysis of the characteristics, complications, and outcomes of a single-center case series of consecutive patients treated with the EXCOR VAD as BTT between 20. The aim of this study was to describe the results of using paracorporeal pulsatile-flow VADs as a bridge to transplant (BTT) in adult patients. Their main limitations include their high cost and inability to provide biventricular support. Most long-term ventricular assist devices (VADs) that are currently implanted are intracorporeal continuous-flow devices.

Susy perez revista para adultos